Reviewer’s report

Title: The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

Version: 0 Date: 04 Oct 2016

Reviewer: Bee Ping Chong

Reviewer's report:

(page 3 line 24) there is no BCR-ABL1/ABL1 level at diagnosis, therefore the reduction of the copies after treatment can't be compared.

(page 3 line 36) what is the meaning of transient hematological response? and did the patient achieve complete hematological response?

(page 4 line 1-8) what was the gap between the 1st and second Blinatumomab treatment?

(page 4 line 23) again what is transient hematological response?

(page 6 line 19 to 31), this part should be under the subtitle of discussion, line 32-46 under the subtitle of conclusion

It will be clearer with a chart/graph of the BCR-ABL transcripts level through out the timeline.

there are too many brackets in the article, example, page 3 line 55: A severe cardiac toxicity (reduction of ejection fraction up to 46%). The authors should try to compose it into a proper sentence.

Overall, this is an interesting case to discuss.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal